Kaitlin J Mayne

17PUBLICATIONS
85CO-AUTHORS
Respiratory diseasesMajor global burdens of diseaseCardiology (incl. cardiovascular diseases)Nephrology and urologySocial epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Oct 24, 2025
Increased risk of cardiac death with cumulative exposure to fluid overload and dialysate sodium ≤138 mmol/l in hemodialysis patients.

Martin Christa, Brendan Smyth, Kaitlin J Mayne

|Apr 03, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.

Kaitlin J Mayne, Rebecca J Sardell, Natalie Staplin

|Nov 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Parminder K Judge, Katherine R Tuttle, Natalie Staplin

|Nov 08, 2024
Associations of Abnormal Fluid Status, Plasma Sodium Disorders, and Low Dialysate Sodium with Mortality in Patients on Hemodialysis.

Jule Pinter, Bernard Canaud, Kaitlin J Mayne

|Sep 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.

Kaitlin J Mayne, Rebecca J Sardell, Natalie Staplin

|Apr 16, 2024
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.

Robert A Fletcher, William G Herrington, Rajiv Agarwal

Pageof 3

Frequent Collaborators

7 joint publications

William G Herrington

5 joint publications

Jennifer S Lees

5 joint publications

Richard Haynes

5 joint publications

Christoph Wanner